In lung cancers, significantly dysregulated lncRNAs have been reported [13], and many of them, e.g., PANDAR [14], DLX6-AS1 [15], BCYRN1 [16], HNF1A-AS1 [17], ANRIL [18], MEG3 [19], and others, are involved in lung cancer pathogenesis, cell proliferation, invasion and metastasis, and drug resistance. This evidence concerns the gene CDKN2B-AS1 and lung carcinoma.